IBRDC1 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-59776
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Synthetic peptides corresponding to RNF217(ring finger protein 217) The peptide sequence was selected from the middle region of RNF217. Peptide sequence GLALGAIAVVIVEEIKTYWNLISGRTRNQTQHLAPQPVLLSDMLYCLKQV. The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Scientific Data Images for IBRDC1 Antibody
Western Blot: IBRDC1 Antibody [NBP1-59776]
Western Blot: IBRDC1 Antibody [NBP1-59776] - Human Heart lysate, concentration 0.2-1 ug/ml.Applications for IBRDC1 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: IBRDC1
Alternate Names
C6orf172, chromosome 6 open reading frame 172, dJ84N20.1, EC 6.3.2.-, IBR domain containing 1, IBRDC1, MGC26996, probable E3 ubiquitin-protein ligase RNF217, ring finger protein 217IBR domain-containing protein 1
Gene Symbol
RNF217
UniProt
Additional IBRDC1 Products
Product Documents for IBRDC1 Antibody
Product Specific Notices for IBRDC1 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...